Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,583.00 | 40.10 | 0.47% |
| CAC 40 | 7,489.35 | 43.66 | 0.59% |
| DAX 40 | 20,340.57 | 124.38 | 0.62% |
| Dow JONES (US) | 42,528.36 | 178.20 | -0.42% |
| FTSE 100 | 8,245.28 | 4.38 | -0.05% |
| HKSE | 19,367.53 | 80.05 | -0.41% |
| NASDAQ | 19,489.68 | 375.30 | -1.89% |
| Nikkei 225 | 39,949.02 | 134.28 | -0.34% |
| NZX 50 Index | 13,046.65 | 4.59 | 0.04% |
| S&P 500 | 5,909.03 | 66.35 | -1.11% |
| S&P/ASX 200 | 8,330.70 | 45.60 | 0.55% |
| SSE Composite Index | 3,226.19 | 3.45 | -0.11% |